Condition: Arthritis, Rheumatoid · Sponsor: Qilu Hospital of Shandong University
This study includes naive patients and csDMARDs-IR RA patients, treated with different regimens such as Iguratimod combination of different csDMARDs, or csDMARD with TNF inhibitors for 24 weeks. The disease activity and drug response will be observed. The immune disorder and synovial function will be evaluated at the same time.
This description comes directly from the study's public registry record.
Qiang Shu, Dr. · 0086-0531-82169654 · shuqiang@sdu.edu.cn
Bingbing Ren · 0086-18765361979 · sdrenbingbing@163.com
Always discuss trial participation with your own doctor first.
| Qilu Hospital | Jinan, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05626348